CD8A and cancer: In addition, patients with cancer who were also transplant recipients rapidly developed allograft rejection after initiation of PD-1–targeted therapies (49), indicating the existence of allograft-specific exhausted CD8+ T cells that responded to PD-1 blockade in transplant recipients.